Clinical Trial Update: A Single-Arm Phase II Clinical Study of Pemigatinib in the Treatment of Advanced Non-Small Cell Lung Cancer Patients With FGFR Alterations Who Have Failed Standard Therapy [Phase 2]

View source ↗

Summary

A single-arm Phase II trial evaluating pemigatinib in advanced non-small cell lung cancer patients with FGFR alterations after failure of standard therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Pemigatinib (pemigatinib)

Snippet

Sponsor: The First Affiliated Hospital of Xiamen University | Conditions: Advanced Non-Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN